Shots:
- Roche has received the European CE Mark approval for Contivue, a port delivery platform containing Susvimo (Lucentis) for the treatment of neovascular age-related macular degeneration (nAMD); Susvimo (100mg/mL) is under the EMA’s review
- Approval was backed by P-III (Archway) trial & additional studies, a P-II (LADDER) trial, & Portal OLE long-term study, with Archway showing vision outcomes equivalent to ranibizumab (intravitreal, QM)
- 7yr. LADDER data (n=59) showed maintained stable anatomy & durable efficacy, with BCVA declining by ~6 letters (70.4 to 63.2), ~50% pts retaining 20/40 vision, & sustained durability in ~95%; data was presented at EURETINA Congress
Ref: Roche | Image: Roche| Press Release
Related News:- Roche Reports P-III (Portal) Trial Data on Susvimo for Neovascular Age-Related Macular Degeneration (nAMD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
